Combination therapy with a sense oligonucleotide to inducible nitric oxide synthase mRNA and human soluble thrombomodulin improves survival of sepsis model rats after partial hepatectomy
Sepsis after a major hepatectomy is a critical problem. In septic shock, the inflammatory mediator, nitric oxide (NO), is overproduced in hepatocytes and macrophages. The natural antisense (AS) transcripts, non-coding RNAs, are transcribed from a gene that encodes inducible nitric oxide synthase (iN...
Gespeichert in:
Veröffentlicht in: | Shock (Augusta, Ga.) Ga.), 2023-07, Vol.60 (1), p.84-91 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 91 |
---|---|
container_issue | 1 |
container_start_page | 84 |
container_title | Shock (Augusta, Ga.) |
container_volume | 60 |
creator | Nakatake, Richi Okuyama, Tetsuya Kotsuka, Masaya Ishizaki, Morihiko Kitade, Hiroaki Yoshizawa, Katsuhiko Tolba, Rene H. Nishizawa, Mikio Sekimoto, Mitsugu |
description | Sepsis after a major hepatectomy is a critical problem. In septic shock, the inflammatory mediator, nitric oxide (NO), is overproduced in hepatocytes and macrophages. The natural antisense (AS) transcripts, non-coding RNAs, are transcribed from a gene that encodes inducible nitric oxide synthase (iNOS). iNOS AS transcripts interact with and stabilize iNOS mRNAs. A single-stranded "sense oligonucleotide" (designated as SO1) corresponding to the iNOS mRNA sequence inhibits mRNA-AS transcript interactions and reduces iNOS mRNA levels in rat hepatocytes. In contrast, recombinant human soluble thrombomodulin (rTM) treats disseminated intravascular coagulopathy by suppressing coagulation, inflammation, and apoptosis. In this study, the combination therapy of SO1 and a low dose of rTM was evaluated for hepatoprotection in a rat septic shock model after partial hepatectomy. Rats underwent 70% hepatectomy, followed by intravenous (i.v.) injection of lipopolysaccharide (LPS) after 48 h. SO1 was injected (i.v.) simultaneously with LPS, whereas rTM was injected (i.v.) 1 h before LPS injection. Similarly to our previous report, SO1 increased survival after LPS injection. When rTM, which has different mechanisms of action, was combined with SO1, it did not interfere with the effect of SO1 and showed a significant increase in survival compared with LPS alone treatment. In serum, the combined treatment decreased NO levels. In the liver, the combined treatment inhibited iNOS mRNA and protein expression. A decreased iNOS AS transcript expression by the combined treatment was also observed. The combined treatment decreased mRNA expression of the inflammatory and pro-apoptotic genes while increasing that of the anti-apoptotic gene. Furthermore, the combined treatment reduced the number of myeloperoxidase-positive cells. These results suggested that the combination of SO1 and rTM has therapeutic potential for sepsis. |
doi_str_mv | 10.1097/SHK.0000000000002135 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2809544574</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2809544574</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3529-c33fbf1ed9e45737116e2d7de52f5f5978b93feebf06862d28217fa5ced14a603</originalsourceid><addsrcrecordid>eNpdkctu1DAYhSMEohd4A4S8ZJPiS5zEy2oEtKKiUgvryIl_E4NjB19mmFfj6fCoA1R4YVvyd86xfarqFcEXBIvu7f3Vxwv8aFDC-JPqlPAG15iT5mnZ447VlFF6Up3F-K0wDRPd8-qEdaQhpO1Pq18bv4zGyWS8Q2mGINc92pk0I4kiuAjIW_PVuzxZ8MkoQMkj41SezGgBOZOCmZD_eTiJe5dmWSTL3adLJJ1Cc16kQ9HbfIDTHEqYX7zK1jhkljX4LUQUc9iarbTI65K5RhNRYcCiIFNEUicIaJUhmYLMsMoEU_LL_kX1TEsb4eVxPa--vH_3eXNV39x-uN5c3tQT41SUmelRE1ACGt6Vl5MWqOoUcKq55qLrR8E0wKhx27dU0Z6STks-gSKNbDE7r948-Jbr_sgQ07CYOIG10oHPcaA9Frwp3k1Bmwd0Cj7GAHpYg1lk2A8ED4fWhtLa8H9rRfb6mJDHBdRf0Z-a_vnuvC2_Eb_bvIMwzCBtmg9-pdie1kIcXWuMiRDsNx7iqAc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2809544574</pqid></control><display><type>article</type><title>Combination therapy with a sense oligonucleotide to inducible nitric oxide synthase mRNA and human soluble thrombomodulin improves survival of sepsis model rats after partial hepatectomy</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Nakatake, Richi ; Okuyama, Tetsuya ; Kotsuka, Masaya ; Ishizaki, Morihiko ; Kitade, Hiroaki ; Yoshizawa, Katsuhiko ; Tolba, Rene H. ; Nishizawa, Mikio ; Sekimoto, Mitsugu</creator><creatorcontrib>Nakatake, Richi ; Okuyama, Tetsuya ; Kotsuka, Masaya ; Ishizaki, Morihiko ; Kitade, Hiroaki ; Yoshizawa, Katsuhiko ; Tolba, Rene H. ; Nishizawa, Mikio ; Sekimoto, Mitsugu</creatorcontrib><description>Sepsis after a major hepatectomy is a critical problem. In septic shock, the inflammatory mediator, nitric oxide (NO), is overproduced in hepatocytes and macrophages. The natural antisense (AS) transcripts, non-coding RNAs, are transcribed from a gene that encodes inducible nitric oxide synthase (iNOS). iNOS AS transcripts interact with and stabilize iNOS mRNAs. A single-stranded "sense oligonucleotide" (designated as SO1) corresponding to the iNOS mRNA sequence inhibits mRNA-AS transcript interactions and reduces iNOS mRNA levels in rat hepatocytes. In contrast, recombinant human soluble thrombomodulin (rTM) treats disseminated intravascular coagulopathy by suppressing coagulation, inflammation, and apoptosis. In this study, the combination therapy of SO1 and a low dose of rTM was evaluated for hepatoprotection in a rat septic shock model after partial hepatectomy. Rats underwent 70% hepatectomy, followed by intravenous (i.v.) injection of lipopolysaccharide (LPS) after 48 h. SO1 was injected (i.v.) simultaneously with LPS, whereas rTM was injected (i.v.) 1 h before LPS injection. Similarly to our previous report, SO1 increased survival after LPS injection. When rTM, which has different mechanisms of action, was combined with SO1, it did not interfere with the effect of SO1 and showed a significant increase in survival compared with LPS alone treatment. In serum, the combined treatment decreased NO levels. In the liver, the combined treatment inhibited iNOS mRNA and protein expression. A decreased iNOS AS transcript expression by the combined treatment was also observed. The combined treatment decreased mRNA expression of the inflammatory and pro-apoptotic genes while increasing that of the anti-apoptotic gene. Furthermore, the combined treatment reduced the number of myeloperoxidase-positive cells. These results suggested that the combination of SO1 and rTM has therapeutic potential for sepsis.</description><identifier>ISSN: 1073-2322</identifier><identifier>EISSN: 1540-0514</identifier><identifier>DOI: 10.1097/SHK.0000000000002135</identifier><identifier>PMID: 37141168</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Hepatectomy ; Humans ; Lipopolysaccharides - pharmacology ; Nitric Oxide - metabolism ; Nitric Oxide Synthase Type II - genetics ; Nitric Oxide Synthase Type II - metabolism ; Oligonucleotides ; RNA, Messenger - metabolism ; Sepsis - drug therapy ; Shock, Septic ; Thrombomodulin - genetics ; Thrombomodulin - metabolism ; Thrombomodulin - therapeutic use</subject><ispartof>Shock (Augusta, Ga.), 2023-07, Vol.60 (1), p.84-91</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2023 by the Shock Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3529-c33fbf1ed9e45737116e2d7de52f5f5978b93feebf06862d28217fa5ced14a603</citedby><cites>FETCH-LOGICAL-c3529-c33fbf1ed9e45737116e2d7de52f5f5978b93feebf06862d28217fa5ced14a603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00024382-990000000-00199$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4595,27901,27902,65206</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37141168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakatake, Richi</creatorcontrib><creatorcontrib>Okuyama, Tetsuya</creatorcontrib><creatorcontrib>Kotsuka, Masaya</creatorcontrib><creatorcontrib>Ishizaki, Morihiko</creatorcontrib><creatorcontrib>Kitade, Hiroaki</creatorcontrib><creatorcontrib>Yoshizawa, Katsuhiko</creatorcontrib><creatorcontrib>Tolba, Rene H.</creatorcontrib><creatorcontrib>Nishizawa, Mikio</creatorcontrib><creatorcontrib>Sekimoto, Mitsugu</creatorcontrib><title>Combination therapy with a sense oligonucleotide to inducible nitric oxide synthase mRNA and human soluble thrombomodulin improves survival of sepsis model rats after partial hepatectomy</title><title>Shock (Augusta, Ga.)</title><addtitle>Shock</addtitle><description>Sepsis after a major hepatectomy is a critical problem. In septic shock, the inflammatory mediator, nitric oxide (NO), is overproduced in hepatocytes and macrophages. The natural antisense (AS) transcripts, non-coding RNAs, are transcribed from a gene that encodes inducible nitric oxide synthase (iNOS). iNOS AS transcripts interact with and stabilize iNOS mRNAs. A single-stranded "sense oligonucleotide" (designated as SO1) corresponding to the iNOS mRNA sequence inhibits mRNA-AS transcript interactions and reduces iNOS mRNA levels in rat hepatocytes. In contrast, recombinant human soluble thrombomodulin (rTM) treats disseminated intravascular coagulopathy by suppressing coagulation, inflammation, and apoptosis. In this study, the combination therapy of SO1 and a low dose of rTM was evaluated for hepatoprotection in a rat septic shock model after partial hepatectomy. Rats underwent 70% hepatectomy, followed by intravenous (i.v.) injection of lipopolysaccharide (LPS) after 48 h. SO1 was injected (i.v.) simultaneously with LPS, whereas rTM was injected (i.v.) 1 h before LPS injection. Similarly to our previous report, SO1 increased survival after LPS injection. When rTM, which has different mechanisms of action, was combined with SO1, it did not interfere with the effect of SO1 and showed a significant increase in survival compared with LPS alone treatment. In serum, the combined treatment decreased NO levels. In the liver, the combined treatment inhibited iNOS mRNA and protein expression. A decreased iNOS AS transcript expression by the combined treatment was also observed. The combined treatment decreased mRNA expression of the inflammatory and pro-apoptotic genes while increasing that of the anti-apoptotic gene. Furthermore, the combined treatment reduced the number of myeloperoxidase-positive cells. These results suggested that the combination of SO1 and rTM has therapeutic potential for sepsis.</description><subject>Hepatectomy</subject><subject>Humans</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase Type II - genetics</subject><subject>Nitric Oxide Synthase Type II - metabolism</subject><subject>Oligonucleotides</subject><subject>RNA, Messenger - metabolism</subject><subject>Sepsis - drug therapy</subject><subject>Shock, Septic</subject><subject>Thrombomodulin - genetics</subject><subject>Thrombomodulin - metabolism</subject><subject>Thrombomodulin - therapeutic use</subject><issn>1073-2322</issn><issn>1540-0514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctu1DAYhSMEohd4A4S8ZJPiS5zEy2oEtKKiUgvryIl_E4NjB19mmFfj6fCoA1R4YVvyd86xfarqFcEXBIvu7f3Vxwv8aFDC-JPqlPAG15iT5mnZ447VlFF6Up3F-K0wDRPd8-qEdaQhpO1Pq18bv4zGyWS8Q2mGINc92pk0I4kiuAjIW_PVuzxZ8MkoQMkj41SezGgBOZOCmZD_eTiJe5dmWSTL3adLJJ1Cc16kQ9HbfIDTHEqYX7zK1jhkljX4LUQUc9iarbTI65K5RhNRYcCiIFNEUicIaJUhmYLMsMoEU_LL_kX1TEsb4eVxPa--vH_3eXNV39x-uN5c3tQT41SUmelRE1ACGt6Vl5MWqOoUcKq55qLrR8E0wKhx27dU0Z6STks-gSKNbDE7r948-Jbr_sgQ07CYOIG10oHPcaA9Frwp3k1Bmwd0Cj7GAHpYg1lk2A8ED4fWhtLa8H9rRfb6mJDHBdRf0Z-a_vnuvC2_Eb_bvIMwzCBtmg9-pdie1kIcXWuMiRDsNx7iqAc</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Nakatake, Richi</creator><creator>Okuyama, Tetsuya</creator><creator>Kotsuka, Masaya</creator><creator>Ishizaki, Morihiko</creator><creator>Kitade, Hiroaki</creator><creator>Yoshizawa, Katsuhiko</creator><creator>Tolba, Rene H.</creator><creator>Nishizawa, Mikio</creator><creator>Sekimoto, Mitsugu</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230701</creationdate><title>Combination therapy with a sense oligonucleotide to inducible nitric oxide synthase mRNA and human soluble thrombomodulin improves survival of sepsis model rats after partial hepatectomy</title><author>Nakatake, Richi ; Okuyama, Tetsuya ; Kotsuka, Masaya ; Ishizaki, Morihiko ; Kitade, Hiroaki ; Yoshizawa, Katsuhiko ; Tolba, Rene H. ; Nishizawa, Mikio ; Sekimoto, Mitsugu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3529-c33fbf1ed9e45737116e2d7de52f5f5978b93feebf06862d28217fa5ced14a603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Hepatectomy</topic><topic>Humans</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase Type II - genetics</topic><topic>Nitric Oxide Synthase Type II - metabolism</topic><topic>Oligonucleotides</topic><topic>RNA, Messenger - metabolism</topic><topic>Sepsis - drug therapy</topic><topic>Shock, Septic</topic><topic>Thrombomodulin - genetics</topic><topic>Thrombomodulin - metabolism</topic><topic>Thrombomodulin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakatake, Richi</creatorcontrib><creatorcontrib>Okuyama, Tetsuya</creatorcontrib><creatorcontrib>Kotsuka, Masaya</creatorcontrib><creatorcontrib>Ishizaki, Morihiko</creatorcontrib><creatorcontrib>Kitade, Hiroaki</creatorcontrib><creatorcontrib>Yoshizawa, Katsuhiko</creatorcontrib><creatorcontrib>Tolba, Rene H.</creatorcontrib><creatorcontrib>Nishizawa, Mikio</creatorcontrib><creatorcontrib>Sekimoto, Mitsugu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Shock (Augusta, Ga.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakatake, Richi</au><au>Okuyama, Tetsuya</au><au>Kotsuka, Masaya</au><au>Ishizaki, Morihiko</au><au>Kitade, Hiroaki</au><au>Yoshizawa, Katsuhiko</au><au>Tolba, Rene H.</au><au>Nishizawa, Mikio</au><au>Sekimoto, Mitsugu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination therapy with a sense oligonucleotide to inducible nitric oxide synthase mRNA and human soluble thrombomodulin improves survival of sepsis model rats after partial hepatectomy</atitle><jtitle>Shock (Augusta, Ga.)</jtitle><addtitle>Shock</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>60</volume><issue>1</issue><spage>84</spage><epage>91</epage><pages>84-91</pages><issn>1073-2322</issn><eissn>1540-0514</eissn><abstract>Sepsis after a major hepatectomy is a critical problem. In septic shock, the inflammatory mediator, nitric oxide (NO), is overproduced in hepatocytes and macrophages. The natural antisense (AS) transcripts, non-coding RNAs, are transcribed from a gene that encodes inducible nitric oxide synthase (iNOS). iNOS AS transcripts interact with and stabilize iNOS mRNAs. A single-stranded "sense oligonucleotide" (designated as SO1) corresponding to the iNOS mRNA sequence inhibits mRNA-AS transcript interactions and reduces iNOS mRNA levels in rat hepatocytes. In contrast, recombinant human soluble thrombomodulin (rTM) treats disseminated intravascular coagulopathy by suppressing coagulation, inflammation, and apoptosis. In this study, the combination therapy of SO1 and a low dose of rTM was evaluated for hepatoprotection in a rat septic shock model after partial hepatectomy. Rats underwent 70% hepatectomy, followed by intravenous (i.v.) injection of lipopolysaccharide (LPS) after 48 h. SO1 was injected (i.v.) simultaneously with LPS, whereas rTM was injected (i.v.) 1 h before LPS injection. Similarly to our previous report, SO1 increased survival after LPS injection. When rTM, which has different mechanisms of action, was combined with SO1, it did not interfere with the effect of SO1 and showed a significant increase in survival compared with LPS alone treatment. In serum, the combined treatment decreased NO levels. In the liver, the combined treatment inhibited iNOS mRNA and protein expression. A decreased iNOS AS transcript expression by the combined treatment was also observed. The combined treatment decreased mRNA expression of the inflammatory and pro-apoptotic genes while increasing that of the anti-apoptotic gene. Furthermore, the combined treatment reduced the number of myeloperoxidase-positive cells. These results suggested that the combination of SO1 and rTM has therapeutic potential for sepsis.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>37141168</pmid><doi>10.1097/SHK.0000000000002135</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1073-2322 |
ispartof | Shock (Augusta, Ga.), 2023-07, Vol.60 (1), p.84-91 |
issn | 1073-2322 1540-0514 |
language | eng |
recordid | cdi_proquest_miscellaneous_2809544574 |
source | MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Hepatectomy Humans Lipopolysaccharides - pharmacology Nitric Oxide - metabolism Nitric Oxide Synthase Type II - genetics Nitric Oxide Synthase Type II - metabolism Oligonucleotides RNA, Messenger - metabolism Sepsis - drug therapy Shock, Septic Thrombomodulin - genetics Thrombomodulin - metabolism Thrombomodulin - therapeutic use |
title | Combination therapy with a sense oligonucleotide to inducible nitric oxide synthase mRNA and human soluble thrombomodulin improves survival of sepsis model rats after partial hepatectomy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T12%3A31%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20therapy%20with%20a%20sense%20oligonucleotide%20to%20inducible%20nitric%20oxide%20synthase%20mRNA%20and%20human%20soluble%20thrombomodulin%20improves%20survival%20of%20sepsis%20model%20rats%20after%20partial%20hepatectomy&rft.jtitle=Shock%20(Augusta,%20Ga.)&rft.au=Nakatake,%20Richi&rft.date=2023-07-01&rft.volume=60&rft.issue=1&rft.spage=84&rft.epage=91&rft.pages=84-91&rft.issn=1073-2322&rft.eissn=1540-0514&rft_id=info:doi/10.1097/SHK.0000000000002135&rft_dat=%3Cproquest_cross%3E2809544574%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2809544574&rft_id=info:pmid/37141168&rfr_iscdi=true |